Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab decreases myocardial inflammation in individuals with acute coronary syndrome (ACS)
25 August 2023 (07:30 - 18:30)
Organised by: 
About the speaker
The Johns Hopkins University School of Medicine, Baltimore (United States of America)
4 More presentations in this session
Doctor Y. Xiao (Changsha, CN)
Doctor S. Cederstrom (Stockholm, SE)
Access the full session
The Event
ESC Congress 2023
25 August - 28 August 2023
